查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1666175

全球细胞表面标记检测市场 - 2025 至 2033 年

Global Cell Surface Markers Detection Market - 2025-2033
出版日期: | 出版商: DataM Intelligence | 英文 159 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

2024 年全球细胞表面标誌检测市场规模达 52 亿美元，预计到 2033 年将达到 107 亿美元，2025-2033 年预测期内的复合年增长率为 8.4%。

细胞表面标誌检测是生物医学研究和临床诊断的关键过程，涉及识别细胞外膜上的特定蛋白质、糖蛋白或其他分子。这些标记作为细胞类型、状态和功能的唯一标识符，使研究人员和临床医生能够区分不同的细胞群，例如免疫细胞、癌细胞或干细胞。这种检测对于诊断疾病、分类细胞类型和指导治疗决策至关重要，特别是在肿瘤学、免疫学和再生医学等领域。

由于精准医疗需求的增加、慢性病发病率的上升和技术的进步，细胞表面标誌检测市场预计将快速成长。市场扩张的动力来自于其在诊断、个人化治疗和药物发现的应用。流式细胞仪、质谱法和免疫组织化学等领先技术以及对早期疾病检测的日益关注，使其成为医疗保健和生物技术行业的重要投资领域。

例如，2024 年 8 月，安捷伦科技推出了其产品组合的最新成员 NovoCyte Opteon 光谱流式细胞仪，该产品能够同时分析 40 多个标记，NovoCyte Opteon 使研究人员能够进行大面板流式细胞仪检测并进行复杂的细胞分析研究。

市场动态：

驱动因素与约束因素

个人化医疗的应用日益增多

个人化医疗中日益增长的应用极大地推动了细胞表面标记检测市场的成长，并预计将在预测期内推动市场的发展。个人化医疗涉及根据特定生物标记（包括细胞表面标记）对患者进行分类，以确定最有效的治疗方法。

例如，在癌症治疗中，检测乳癌患者中的 HER2 标记有助于识别那些可以从曲妥珠单抗等 HER2 标靶疗法中受益的患者。同样，PD-L1 等标记物可以指导免疫检查点抑制剂在肺癌中的使用。这种分层确保患者接受最合适、最有效的治疗，从而增加了对精确的细胞表面标誌检测技术的需求。

此外，旨在与特定细胞表面标记物相互作用的标靶疗法的兴起是个人化医疗的基石。单株抗体、CAR-T细胞疗法和小分子抑制剂的开发针对CD20、CD19和EGFR等标记物，提供更精准、毒性更小的治疗选择。

在白血病中，特别是急性淋巴细胞白血病 (ALL) 和慢性淋巴细胞白血病 (CLL)，检测特定的细胞表面标誌对于监测微小残留疾病 (MRD) 至关重要，MRD 是指治疗后残留的少量癌细胞，可能导致復发。 CD19、CD20 和 CD34 等标记用于识别 MRD，指导进一步的治疗决策并改善患者预后。因此，个人化医疗的兴起正在改变疾病的诊断、治疗和管理方式，大大增加了对细胞表面标记检测技术的需求。

类似地，在多发性硬化症中，CD52 标记物是阿崙单抗的标靶药物，阿崙单抗是一种单株抗体，可选择性地消耗导致病情进展的免疫细胞。这些标靶治疗依赖细胞表面标誌的准确检测，这对于选择正确的患者和监测治疗效果至关重要。

标靶标记物可用性有限

目标细胞表面标记的有限可用性限制了全球细胞表面标记检测市场，从而限制了先进检测技术的发展和应用。标靶标记对于精准诊断和个人化治疗策略至关重要，但其有限的发现和验证可能会影响检测方法的有效性和范围。

例如，儘管生物标记研究取得了重大进展，但经过充分验证的细胞表面标记的数量仍然有限。例如，虽然 PD-L1 和 CD19 等标记已得到充分证实并广泛应用于癌症免疫治疗，但对于许多其他癌症或复杂疾病，经过验证的标记物较少。缺乏针对各种情况的全面标记物面板限制了开发有针对性的检测方法的能力，并阻碍了个人化医疗的进展。

此外，发现和验证新的细胞表面标誌需要大量的研究和开发，这可能耗费大量时间和资源。识别新的标记需要大规模研究和临床试验来确定其相关性和可靠性。例如，发现罕见癌症或特定亚型疾病的新标记通常需要大量的研究投资和机构间的合作。

目录

第一章：市场介绍和范围

  • 报告目标
  • 报告范围和定义
  • 报告范围

第 2 章：高阶主管见解与关键要点

  • 市场亮点和战略要点
  • 主要趋势和未来预测
  • 按产品类型分类的片段
  • 按应用程式截取的程式码片段
  • 按地区分类的片段

第 3 章：动态

  • 影响因素
    • 驱动程式
      • 个人化医疗中日益增多的应用
    • 限制
      • 标靶标记物的可用性有限
    • 机会
    • 影响分析

第四章：战略洞察与产业展望

  • 市场领导者和先驱者
    • 新兴先锋和杰出参与者
    • 拥有最大销售品牌的成熟领导者
    • 拥有成熟产品的市场领导者
  • CXO 观点
  • 最新进展与突破
  • 案例研究/正在进行的研究
  • 监管和报销情况
    • 北美洲
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲
  • 波特五力分析
  • 供应链分析
  • 专利分析
  • SWOT 分析
  • 未满足的需求和差距
  • 市场进入和扩张的推荐策略
  • 情境分析：最佳情况、基本情况和最坏情况预测
  • 定价分析和价格动态
  • 关键意见领袖

第 5 章：细胞表面标记检测市场（依产品类型）

  • 流式细胞仪
  • 血液学分析仪
  • 细胞成像系统
  • 试剂和试剂盒
  • 其他的

第 6 章：细胞表面标记检测市场（依应用）

  • 疾病诊断与鑑定
  • 研究与药物发现
  • 其他的

第 7 章：细胞表面标记检测市场，按区域市场分析和成长机会

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 义大利
    • 欧洲其他地区
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地区
  • 亚太
    • 中国
    • 印度
    • 日本
    • 韩国
    • 亚太其他地区
  • 中东和非洲

第 8 章：竞争格局与市场定位

  • 竞争概况和主要市场参与者
  • 市占率分析与定位矩阵
  • 策略伙伴关係、併购
  • 产品组合和创新的关键发展
  • 公司基准化分析

第九章：公司简介

  • Becton, Dickinson, and Company
    • 公司概况
    • 产品组合和描述
    • 财务概览
    • 主要进展
    • SWOT 分析
  • NIHON KOHDEN CORPORATION
  • Sysmex Corporation
  • Thermo Fisher Scientific Inc.
  • Nexcelom Bioscience LLC
  • Beckman Coulter, Inc.
  • Agilent Technologies Inc.
  • Bio-Rad Laboratories, Inc.
  • Cytek Biosciences Inc
  • Miltenyi Biotec

第 10 章：假设与研究方法

  • 资料收集方法
  • 数据三角测量
  • 预测技术
  • 数据验证和确认

第 11 章：附录

简介目录
Product Code: MD3902

The global cell surface markers detection market reached US$ 5.2 billion in 2024 and is expected to reach US$ 10.7 billion by 2033, growing at a CAGR of 8.4% during the forecast period 2025-2033.

Cell surface marker detection is a critical process in biomedical research and clinical diagnostics that involves identifying specific proteins, glycoproteins or other molecules on the outer membrane of cells. These markers serve as unique identifiers of cell types, states and functions, enabling researchers and clinicians to distinguish between different cell populations, such as immune cells, cancer cells or stem cells. This detection is vital for diagnosing diseases, classifying cell types and guiding therapeutic decisions, especially in fields like oncology, immunology and regenerative medicine.

The cell surface marker detection market is expected to grow rapidly due to increasing demand for precision medicine, rising incidences of chronic diseases and technological advancements. The market's expansion is driven by its applications in diagnostics, personalized therapy and drug discovery. Leading technologies like flow cytometry, mass spectrometry and immunohistochemistry, along with the growing focus on early disease detection, make this an essential area of investment in both the healthcare and biotechnology industries.

For instance, in August 2024, Agilent Technologies unveiled the latest addition to its portfolio, the NovoCyte Opteon Spectral Flow Cytometer which is capable of simultaneously analyzing over 40 markers, the NovoCyte Opteon enables researchers to conduct large-panel flow cytometry assays and undertake sophisticated cell analysis research.

Market Dynamics: Drivers & Restraints

Rising applications in personalized medicine

The rising applications in personalized medicine are significantly driving the growth of the cell surface markers detection market and are expected to drive the market over the forecast period. Personalized medicine involves categorizing patients based on specific biomarkers, including cell surface markers, to determine the most effective treatment.

For instance, in cancer treatment, the detection of HER2 markers in breast cancer patients helps identify those who would benefit from HER2-targeted therapies like trastuzumab. Similarly, markers like PD-L1 guide the use of immune checkpoint inhibitors in lung cancer. This stratification ensures that patients receive the most appropriate and potentially effective treatment, increasing the demand for accurate cell surface marker detection technologies.

Additionally, the rise in targeted therapies, which are designed to interact with specific cell surface markers, is a cornerstone of personalized medicine. Monoclonal antibodies, CAR-T cell therapies, and small molecule inhibitors are developed to target markers such as CD20, CD19 and EGFR, providing more precise and less toxic treatment options.

In leukemia, particularly acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL), the detection of specific cell surface markers is crucial for monitoring minimal residual disease (MRD), which refers to the small number of cancer cells that remain after treatment and may lead to relapse. Markers like CD19, CD20 and CD34 are used to identify MRD, guiding further treatment decisions and improving patient prognosis. Thus, rising personalized medicine is transforming how diseases are diagnosed, treated and managed, significantly boosting the demand for cell surface marker detection technologies.

Similarly, in multiple sclerosis, CD52 markers are targeted by alemtuzumab, a monoclonal antibody that selectively depletes immune cells contributing to disease progression. These targeted therapies rely on the accurate detection of cell surface markers, which is essential for selecting the right patients and monitoring therapeutic efficacy.

Limited availability of targeted markers

The limited availability of targeted cell surface markers significantly restrains the global cell surface markers detection market by constraining the development and application of advanced detection technologies. Targeted markers are crucial for precise diagnostics and personalized treatment strategies, but their limited discovery and validation can impact the effectiveness and scope of detection methods.

For instance, despite significant advancements in biomarker research, the number of well-validated cell surface markers remains limited. For instance, while markers like PD-L1 and CD19 are well-established and widely used in cancer immunotherapy, there are fewer validated markers for many other cancers or complex diseases. The lack of comprehensive marker panels for various conditions limits the ability to develop targeted detection methods and hinders progress in personalized medicine.

Additionally, discovering and validating new cell surface markers involves extensive research and development, which can be time-consuming and resource-intensive. Identifying novel markers requires large-scale studies and clinical trials to establish their relevance and reliability. For instance, discovering new markers for rare cancers or specific subtypes of diseases often requires significant investment in research and collaboration between institutions.

Segment Analysis

The global cell surface markers detection market is segmented based on product type, application and region.

Product Type:

The flow cytometers segment is expected to dominate the cell surface markers detection market share

Flow cytometers are a laser-based technology used for cell counting, biomarker detection, cell sorting and protein engineering. It helps identify, characterize and isolate stem and progenitor cells for research and clinical use. The growing adoption of flow cytometry in stem cell research and its increasing applications in clinical research are expected to drive the segment's growth.

Flow cytometers aid in the identification, characterization and isolation of stem and progenitor cells for research and clinical use. It simplifies disease analysis, sample separation and diagnosis, and its increasing applications in clinical research are expected to drive market growth. For instance, in May 2024, Agilent Technologies Inc. unveiled the NovoCyte Opteon Spectral Flow Cytometer, offering configurations ranging from three to five lasers and supporting up to 73 high-quality detectors.

The analysis of cell-surface proteins by flow cytometry produces robust and quantitative information with single-cell resolution and allows live target cells to be purified and characterized or re-cultured. Various studies using antibody screens, proteomics and candidate analysis have identified a comprehensive set of proteins that are expressed on the surface of primed human pluripotent stem cells. For instance, in June 2024, Lund University's Biomedical Centre added a high-tech spectral flow cytometry instrument to its FACS Core Facility, enhancing speed and precision in cell research.

Geographical Analysis

North America is expected to hold a significant position in the cell surface markers detection market share

North America especially the United States leads global efforts in cancer research, with government initiatives such as the "Cancer Moonshot" driving research into immunotherapy, personalized medicine and biomarker detection. Cell surface markers are vital in this field, particularly for identifying specific populations of cancer cells and immune cells (like T cells) for diagnostics, prognostics and therapies. Companies like Thermo Fisher Scientific, Bio-Rad Laboratories and BD Biosciences are headquartered in the United States, dominating the market with cutting-edge technologies for cell marker detection.

For instance, on March 26, 2024, Bio-Rad Laboratories, Inc., launched validated antibodies for rare and circulating tumor cell (CTC) enumeration. Validated for use with Bio-Rad's Celselect Slides Enumeration Stain Kits, the antibodies are specific to CTC surface markers to enable the sensitive and specific identification of target cell populations, enhancing the study of tumor heterogeneity and disease progression at various stages. Bio-Rad's Genesis Cell Isolation System captures a wide range of CTCs and other rare cells from liquid biopsy samples. After capture, the cells can be recovered for downstream analysis or immunostained on-slide for immunofluorescence applications such as enumeration and identification of various CTC types.

In North America, the rising prevalence of cancer and chronic diseases has led to increased investment in cell surface marker detection. These markers are crucial for early diagnosis, patient stratification and monitoring treatment responses.

For instance, according to the National Institute of Health (NIH), in 2024, roughly 2.0 million people will be diagnosed with cancer in the United States. An estimated 310,720 women and 2,790 men will be diagnosed with breast cancer. Prostate cancer is the leading cancer diagnosis among men and the second most common diagnosis overall with 299,010 expected cases. Lung and bronchus cancer is the third most common cancer diagnosis with an estimated 234,580 new cases.

Additionally, in 2024, an estimated 611,720 people will die of cancer in the United States. Lung and bronchus cancer is responsible for the most deaths with 125,070 people expected to die from this disease. That is nearly three times the 53,010 deaths due to colorectal cancer, which is the second most common cause of cancer death. Pancreatic cancer is the third deadliest cancer, causing 51,750 deaths. This increasing prevalence of cancers and various chronic diseases may increase the demand for the cell surface marker detection market.

North America, particularly the United States has a strong presence of leading biotechnology and life sciences companies, including Bio-Rad Laboratories, Beckman Coulter and Thermo Fisher Scientific, which are continuously launching new products for cell surface marker detection. These advancements often center around flow cytometry and imaging technologies, both crucial for high-throughput and accurate cell marker identification.

For instance, in March 2024, Beckman Coulter Life Sciences received 510(k) clearance from the Food and Drug Administration (FDA) to distribute its DxFLEX Clinical Flow Cytometer in the United States. Launched regionally in 2020, this advancement brings the popular benchtop IVD flow cytometry system to American labs while expanding testing capabilities. Offering up to 13 colors, additional detectors can be activated as laboratory needs evolve without the need to purchase additional hardware.

Asia-Pacific is growing at the fastest pace in the Cell Surface Markers Detection market

The demand for cell surface markers detection in the Asia-Pacific region, including major countries like China, India, Japan, South Korea and others, is experiencing rapid growth. This growth is driven by the increasing prevalence of chronic diseases such as cancer, autoimmune disorders and infectious diseases, coupled with rising investments in biotechnology and healthcare infrastructure. The Asia-Pacific region is emerging as a key region in the global cell surface marker detection market, with the expansion of research and development activities, growing adoption of advanced diagnostics and government initiatives aimed at improving healthcare.

China has one of the highest cancer rates, particularly for lung, breast and gastrointestinal cancers. This has led to a significant increase in demand for early detection technologies, including cell surface marker detection, which is critical for diagnostics and treatment monitoring. China's government has made substantial investments in cancer research, with institutions like the National Cancer Center of China playing a pivotal role in advancing cancer immunotherapy and personalized medicine.

For instance, according to the National Institute of Health, lung cancer is the most common cancer in China in 2022 (1,060,600 cases), followed by colorectal cancer (517,100 cases), thyroid cancer (466,100 cases), liver cancer (367,700 cases) and stomach cancer (358,700 cases), accounting for 57.42% of total new cancer cases. This is suspected to boost the market in the region.

India is witnessing a rise in cancer cases, particularly breast and cervical cancer. Additionally, the country faces a high burden of infectious diseases like tuberculosis and HIV. The detection of cell surface markers is essential in both oncology and infectious disease diagnostics. The Indian government, along with private healthcare companies like Dr. Reddy's Laboratories and Biocon, is increasingly focusing on cancer research and diagnostic improvements, which is driving the demand for advanced detection technologies.

For instance, according to the National Institute of Health, in India, the incidence of cancer cases is likely to increase from 1.46 million in 2022 to 1.57 million in 2025. Lung cancer was estimated to be 1,03,371 cases in 2022 and it featured in the top five leading sites for both males and females. The estimates for cancer in India increased by five percent (14,61,427 in 2022 compared to 13,92,179 in 2020). This directly boosts the demand for cell surface markers detection market in India.

China is rapidly advancing its capabilities in precision oncology. With the government's "Healthy China 2030" plan prioritizing cancer care and innovative treatments, cell surface marker detection has become integral to research and clinical trials. Companies are at the forefront of developing targeted therapies that depend on accurate detection of markers such as PD-L1 and CD20.

Competitive Landscape

The major global players in the cell surface markers detection market include Becton, Dickinson, and Company, NIHON KOHDEN CORPORATION, Sysmex Corporation, Thermo Fisher Scientific Inc., Nexcelom Bioscience LLC, Beckman Coulter, Inc., Agilent Technologies Inc., Bio-Rad Laboratories, Inc., Cytek Biosciences Inc, Miltenyi Biotec and among others.

Why Purchase the Report?

  • Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
  • Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global cell surface markers detection market report delivers a detailed analysis with 54 key tables, more than 44 visually impactful figures, and 159 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

  • Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.

Table of Contents

1. Market Introduction and Scope

  • 1.1. Objectives of the Report
  • 1.2. Report Coverage & Definitions
  • 1.3. Report Scope

2. Executive Insights and Key Takeaways

  • 2.1. Market Highlights and Strategic Takeaways
  • 2.2. Key Trends and Future Projections
  • 2.3. Snippet by Product Type
  • 2.4. Snippet by Application
  • 2.5. Snippet by Region

3. Dynamics

  • 3.1. Impacting Factors
    • 3.1.1. Drivers
      • 3.1.1.1. Rising Applications in Personalized Medicine
    • 3.1.2. Restraints
      • 3.1.2.1. Limited Availability of Targeted Markers
    • 3.1.3. Opportunity
    • 3.1.4. Impact Analysis

4. Strategic Insights and Industry Outlook

  • 4.1. Market Leaders and Pioneers
    • 4.1.1. Emerging Pioneers and Prominent Players
    • 4.1.2. Established leaders with largest selling Brand
    • 4.1.3. Market leaders with established Product
  • 4.2. CXO Perspectives
  • 4.3. Latest Developments and Breakthroughs
  • 4.4. Case Studies/Ongoing Research
  • 4.5. Regulatory and Reimbursement Landscape
    • 4.5.1. North America
    • 4.5.2. Europe
    • 4.5.3. Asia Pacific
    • 4.5.4. Latin America
    • 4.5.5. Middle East & Africa
  • 4.6. Porter's Five Force Analysis
  • 4.7. Supply Chain Analysis
  • 4.8. Patent Analysis
  • 4.9. SWOT Analysis
  • 4.10. Unmet Needs and Gaps
  • 4.11. Recommended Strategies for Market Entry and Expansion
  • 4.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
  • 4.13. Pricing Analysis and Price Dynamics
  • 4.14. Key Opinion Leaders

5. Cell Surface Markers Detection Market, By Product Type

  • 5.1. Introduction
    • 5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 5.1.2. Market Attractiveness Index, By Product Type
  • 5.2. Flow Cytometry*
    • 5.2.1. Introduction
    • 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 5.3. Hematology Analyzers
  • 5.4. Cell Imaging Systems
  • 5.5. Reagents and Kits
  • 5.6. Others

6. Cell Surface Markers Detection Market, By Application

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 6.1.2. Market Attractiveness Index, By Application
  • 6.2. Disease Diagnosis and Identification*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Research & Drug Discovery
  • 6.4. Others

7. Cell Surface Markers Detection Market, By Regional Market Analysis and Growth Opportunities

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 7.1.2. Market Attractiveness Index, By Region
  • 7.2. North America
    • 7.2.1. Introduction
    • 7.2.2. Key Region-Specific Dynamics
    • 7.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 7.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 7.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 7.2.5.1. U.S.
      • 7.2.5.2. Canada
      • 7.2.5.3. Mexico
  • 7.3. Europe
    • 7.3.1. Introduction
    • 7.3.2. Key Region-Specific Dynamics
    • 7.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 7.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 7.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 7.3.5.1. Germany
      • 7.3.5.2. U.K.
      • 7.3.5.3. France
      • 7.3.5.4. Spain
      • 7.3.5.5. Italy
      • 7.3.5.6. Rest of Europe
  • 7.4. South America
    • 7.4.1. Introduction
    • 7.4.2. Key Region-Specific Dynamics
    • 7.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 7.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 7.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 7.4.5.1. Brazil
      • 7.4.5.2. Argentina
      • 7.4.5.3. Rest of South America
  • 7.5. Asia-Pacific
    • 7.5.1. Introduction
    • 7.5.2. Key Region-Specific Dynamics
    • 7.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 7.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 7.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 7.5.5.1. China
      • 7.5.5.2. India
      • 7.5.5.3. Japan
      • 7.5.5.4. South Korea
      • 7.5.5.5. Rest of Asia-Pacific
  • 7.6. Middle East and Africa
    • 7.6.1. Introduction
    • 7.6.2. Key Region-Specific Dynamics
    • 7.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 7.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application

8. Competitive Landscape and Market Positioning

  • 8.1. Competitive Overview and Key Market Players
  • 8.2. Market Share Analysis and Positioning Matrix
  • 8.3. Strategic Partnerships, Mergers & Acquisitions
  • 8.4. Key Developments in Product Portfolios and Innovations
  • 8.5. Company Benchmarking

9. Company Profiles

  • 9.1. Becton, Dickinson, and Company*
    • 9.1.1. Company Overview
    • 9.1.2. Product Portfolio and Description
    • 9.1.3. Financial Overview
    • 9.1.4. Key Developments
    • 9.1.5. SWOT Analysis
  • 9.2. NIHON KOHDEN CORPORATION
  • 9.3. Sysmex Corporation
  • 9.4. Thermo Fisher Scientific Inc.
  • 9.5. Nexcelom Bioscience LLC
  • 9.6. Beckman Coulter, Inc.
  • 9.7. Agilent Technologies Inc.
  • 9.8. Bio-Rad Laboratories, Inc.
  • 9.9. Cytek Biosciences Inc
  • 9.10. Miltenyi Biotec

LIST NOT EXHAUSTIVE

10. Assumption and Research Methodology

  • 10.1. Data Collection Methods
  • 10.2. Data Triangulation
  • 10.3. Forecasting Techniques
  • 10.4. Data Verification and Validation

11. Appendix

  • 11.1. About Us and Services
  • 11.2. Contact Us